Lisa Marten
Ophthalmology · San Antonio, TXNPI 1861527483
Payments from drug & device makers
Across 160 payments — averaging $212.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$27K
- Carl Zeiss Meditec USA, Inc.$2K
- Alcon$1K
- Biotissue Holdings Inc.$805
- AbbVie$688
- Bausch & Lomb Americas Inc.$468
- plus $2K from 16 others
What the payments were for
- Travel & lodging$2,69732%
- Food & beverage$5,67266%
- Education$70%
- Gifts$190%
- Entertainment$1382%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 34 | $27,336 |
| Carl Zeiss Meditec USA, Inc. | 6 | $1,726 |
| Alcon | 39 | $1,059 |
| Biotissue Holdings Inc. | 9 | $805 |
| AbbVie(2 entities) | 20 | $688 |
| Bausch & Lomb Americas Inc. | 10 | $468 |
| Carl Zeiss Meditec, Inc. | 8 | $365 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $333 |
| Ocular Therapeutix, Inc. | 5 | $238 |
| Harrow Eye, LLC | 1 | $178 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $159 |
| Aerie Pharmaceuticals, Inc. | 3 | $142 |
| Optos, Inc. | 1 | $138 |
| Genentech USA, Inc. | 1 | $117 |
| Staar Surgical Company | 1 | $109 |
| Sun Pharmaceutical Industries Inc. | 2 | $45 |
| Novartis | 2 | $42 |
| Rayner Intraocular Lenses Limited | 2 | $40 |
| Amgen | 2 | $31 |
| Oyster Point Pharma, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Katena Products, Inc. (dba Corza Medical) | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARTEVO 800$1,401
- VisuMax$1,269
- CIRRUS HD-OCT$1,011
- IOLMaster 700$1,011
- QUATERA 700$1,011
- Prokera$304
- AmnioGraft$304
- IHEEZO$178
- P200DTx$138
- P200T$138
- P200TE$138
- P200TxE$138
- DURYSTA$135
- Centurion$133
- Clareon$132
- Tecnis IOL$117
- Tecnis Simplicity$117
- VERITAS Vision System$117
- Lucentis$117
- enVista MX60 IOL$115
How this compares
$34,068 in reported general payments places this provider in the 85th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 61 | $99,654 |
| LumiganBimatoprost | 53 | $34,831 |
| IlevroNepafenac | 91 | $34,792 |
| Prednisolone Acetate | 856 | $30,366 |
| MoxifloxacinMoxifloxacin Hcl | 456 | $14,928 |
| Gatifloxacin | 283 | $11,145 |
| Bromfenac Sodium | 97 | $10,884 |
| Restasis MultidoseCyclosporine | 11 | $7,808 |
| ProlensaBromfenac Sodium | 20 | $7,244 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $6,130 |
| Latanoprost | 335 | $4,191 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 24 | $3,855 |
| VyzultaLatanoprostene Bunod | 12 | $3,742 |
| ValacyclovirValacyclovir Hcl | 15 | $1,550 |
| Travoprost | 12 | $1,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Restasis Multidose, Combigan | $688 | $148,423141 claims |
| NovartisIlevro | $42 | $34,79291 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $333 | $7,24420 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $468 | $3,74212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in San Antonio
- Michael SingerSan Antonio$4.2M
- Gregory ParkhurstSan Antonio$4.1M
- Calvin MeinSan Antonio$1.3M
- James LehmannSan Antonio$1.1M
- Darren BellSan Antonio$906K
- Gregory BruninSan Antonio$709K
- Richard EvansSan Antonio$656K
- Edward RashidSan Antonio$523K
- Kenneth MaverickSan Antonio$485K
- Kundandeep NagiSan Antonio$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.